<DOC>
	<DOCNO>NCT00443573</DOCNO>
	<brief_summary>This multicenter , two-stage trial goal evaluate 100 subject . This trial perform initiate identification safe effective dose twice-weekly , subcutaneous rNAPc2 second-line treatment metastatic colorectal carcinoma combination contemporary 5-FU-based chemotherapy .</brief_summary>
	<brief_title>Safety Study Recombinant NAPc2 Prevent Tumor Progression Metastases Metastatic Colon Cancer</brief_title>
	<detailed_description>Cytotoxic chemotherapy combine 5-fluorouracil leucovorin irinotecan ( FOLFIRI ) oxaliplatin ( FOLFOX ) , recently , treatment XELOX ( Roche ) ( capecitabine + oxaliplatin ) main approach treatment metastatic colorectal carcinoma ( mCRC ) , advent target therapy , biologic treatment become area intense interest . Tissue factor ( TF ) transmembrane glycoprotein express upwards 85 % mCRCs .</detailed_description>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Protein C</mesh_term>
	<criteria>Tissue diagnosis adenocarcinoma colon rectum Documented metastatic disease least one measurable lesion RECIST criterion Previously treat 5FUbased chemotherapy form FOLFIRI , FOLFOX , XELOX plus bevacizumab firstline chemotherapy record progressive disease treatment discontinuation treatment , discontinuation treatment occur less 6 month enrollment ( Stage I ) randomization ( Stage II ) Estimated life expectancy least 6 month Age 18 75 year Last dose adjuvant radiosensitizing chemotherapy le 6 month enrollment No active malignancy subject currently receive treatment ( mCRC ) No ongoing therapy need parenteral oral antithrombotics include anticoagulant antiplatelet agent ( include aspirin ) thrombolytics No contraindication systemic anticoagulation No contraindication modify FOLFOX6 FOLFIRI combination chemotherapy No receipt investigational compound within 28 day enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>metastatic colorectal carcinoma ( mCRC )</keyword>
	<keyword>colorectal carcinoma ( CRC )</keyword>
	<keyword>tissue factor</keyword>
	<keyword>factor VIIa</keyword>
	<keyword>rNAPc2</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>target therapy</keyword>
	<keyword>coagulation-dependent</keyword>
	<keyword>RECIST</keyword>
	<keyword>5-FU-based chemotherapy</keyword>
	<keyword>FOLFOX</keyword>
	<keyword>FOLFIRI</keyword>
	<keyword>leucovorin</keyword>
	<keyword>XELOX</keyword>
</DOC>